<DOC>
	<DOCNO>NCT00489918</DOCNO>
	<brief_summary>A Multi-center study determine effect various dos Macroflux PTH woman osteoporosis</brief_summary>
	<brief_title>Dose Ranging Study - Macroflux PTH Postmenopausal Women With Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Healthy postmenopausal woman age 50 year old At least three lumbar vertebra ( L1L4 ) must evaluable DXA BMD , without fracture significant degenerative disease , determined central image facility Have osteoporosis define : Either Tscore ≤ 2.5 lumbar spine , femoral neck , total hip , AND Tscore least &lt; 1.0 lumbar spine ; A Tscore ≤ 2.0 lumbar spine , femoral neck , total hip , AND least one vertebral fracture ; Active hepatitis ; Active pancreatitis ; Unstable cardiac disease ; Unstable pulmonary disease ; Celiac disease ; Hyper hypoparathyroidism ; Hyperthyroidism ; Cushing 's disease ; Osteomalacia ; Paget 's disease ; Osteogenesis imperfecta ; Known blood disorder ; History kidney stone ; Impaired renal function ; Autoimmune diseases ; Bone metastases history skeletal malignancy ; Cancer history include cancer within previous 5 year , exception squamous basal cell carcinoma skin lesion fully resect clear margin describe write report pathologist , patient recurrence lesion least 1 year time original resection ; Any condition disease may interfere ability evaluation DXA scan , example , severe osteoarthritis spine , spinal fusion , pedicle screw , history vertebroplasty , degenerative disease result insufficient number evaluable lumbar vertebra , &gt; 1 lumbar vertebral fracture L1L4 ; More 4 vertebral fracture T4L4 ; Bilateral hip replacement ; Use fluoride ( e.g . fluoride therapy osteoporosis ) strontium time ; Have receive methotrexate immunomodulatory agent antiproliferative activity ; With know dermatological disorder would interfere study procedure assessment , history contact dermatitis ; With know allergy sensitivity tape , adhesive , PTH , teriparatide analog , component Macroflux® system ; Who , opinion investigator , participate study , may capable follow study schedule reason ; Unwillingness inability abide requirement study . Have receive intravenous ( IV ) administer bisphosphonates past 24 month , &gt; 2 dos IV administer bisphosphonates total ; Use oral bisphosphonates randomization , include investigational bisphosphonates , unless : &lt; 6 month treatment 6 month , 612 month treatment 2 year , &gt; 12 month treatment 5 year ;</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>